NexMed Provides Update on NM100060 Phase I U.S. Study

NexMed, a developer of innovative transdermal treatments based on its proprietary NexACT drug delivery technology, has achieved 90 percent patient enrollment in its U.S. Phase I clinical trial of NM100060, its proprietary lacquer treatment of nail fungus (onychomycosis).

The study is double-blind, randomized, parallel designed to assess the safety and pharmacokinetics of NM100060. In the study, the nail lacquer is applied for 28 days by patients with onychomycosis.

The company expects to announce the clinical results during second quarter 2005. Pending satisfactory FDA concurrence and the availability of financing, the company intends to initiate U.S. Phase III trials during the second half of 2005.